Charles Marlowe

While at COR Therapeutics, Millennium Pharmaceuticals, Takeda, and Exelixis Inc., Dr. Chuck Marlowe was instrumental in helping drive a number of small molecule therapeutics to entry into later-stage clinical trials and FDA approval. These products include Integrilin and Betrixaban (FDA-approved), Cromafiban, XL147 and XL765 (Phase II, with Sanofi) and Elinogrel Phase III, with Novartis.

He has worked in a number of fields including agricultural chemistry with Dow Chemical, biotechnology with Chiron Corporation (now Novartis Pharmaceuticals), and medicinal chemistry.

Most recently Chuck was the Principal of Pharmaceutical Consultants, supplying chemical expertise to startup companies in the pharmaceutical, biotechnology, fermentation, and renewable synthetic biology space.

Chuck has authored over 30 publications in leading journals and holds over 25 issued world and US patents. He holds a Ph.D. in organic chemistry from UC Berkeley and was an NIH Postdoctoral fellow at Stanford University.